{"id":"albumin-interferon-alfa-2b","safety":{"commonSideEffects":[{"rate":"null","effect":"Flu-like symptoms"},{"rate":"null","effect":"Fatigue"},{"rate":"null","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL1201558","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Interferon alfa-2b is a cytokine that plays a key role in the body's immune response, particularly in the activation of immune cells and the production of antiviral proteins. By fusing it to albumin, the half-life of interferon alfa-2b is increased, allowing for more sustained therapeutic effects.","oneSentence":"Albumin interferon alfa-2b is a recombinant form of interferon alfa-2b fused to human albumin, which is used to enhance its half-life and therapeutic effects.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:44:17.218Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hepatitis B"}]},"trialDetails":[{"nctId":"NCT03294798","phase":"PHASE1, PHASE2","title":"Study of Recombinant Human Serum Albumin/Interferon alpha2b Fusion Protein in Hepatitis B Patient","status":"COMPLETED","sponsor":"Tianjin SinoBiotech Ltd.","startDate":"2017-06-13","conditions":"Hepatitis B Virus","enrollment":11},{"nctId":"NCT02781753","phase":"PHASE1","title":"Study of Recombinant Human Serum Albumin/Interferon alpha2b Fusion Protein in Chinese Healthy Volunteers","status":"COMPLETED","sponsor":"Tianjin SinoBiotech Ltd.","startDate":"2016-04-07","conditions":"Healthy","enrollment":34},{"nctId":"NCT00759200","phase":"PHASE2","title":"Safety and Efficacy of Albumin Interferon Administered Every 4 Weeks in Genotype 2/3 Hepatitis C Patients","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-10","conditions":"Chronic Hepatitis C","enrollment":525},{"nctId":"NCT00402428","phase":"PHASE3","title":"Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared With Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients","status":"COMPLETED","sponsor":"Human Genome Sciences Inc.","startDate":"2006-12","conditions":"Chronic Hepatitis C","enrollment":1331},{"nctId":"NCT00411385","phase":"PHASE3","title":"Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared to Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients Geno2/3","status":"COMPLETED","sponsor":"Human Genome Sciences Inc.","startDate":"2007-02","conditions":"Chronic Hepatitis C","enrollment":933},{"nctId":"NCT00970996","phase":"PHASE1","title":"Cisplatin, Temozolomide, Abraxane, With Interleukin-2 and Interferon for Metastatic Melanoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2009-09","conditions":"Melanoma","enrollment":10}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":12,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"albumin interferon alfa-2b","genericName":"albumin interferon alfa-2b","companyName":"Human Genome Sciences Inc.","companyId":"human-genome-sciences-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Albumin interferon alfa-2b is a fusion protein composed of human serum albumin and interferon alpha2b, which has been studied in clinical trials for conditions such as Hepatitis B Virus, Chronic Hepatitis C, and Melanoma. The drug has been evaluated in a study (NCT03294798) for its pharmacokinetic and pharmacodynamic profile, safety, and tolerability in patients with Hepatitis B.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}